Abstract 4058
Background
For individual treatment planning in patients with metastatic castration resistant prostate cancer (mCRPC), molecular analyses are increasingly used. As most patients have bone only disease, bone biopsies are often the only source for tumour tissue. However, the success rate of computed tomography (CT)-guided bone biopsies for molecular analyses in mCRPC patients is only 36.5-44%. Positron emission tomography (PET) using 68Ga-PSMA is a promising tool to increase the success rate of bone biopsies for molecular analyses in mCRPC patients.
Methods
In this multicenter study, the success rate of 68Ga-PSMA guided bone biopsies for molecular diagnostics was retrospectively evaluated in a subset of mCRPC patients who underwent a bone biopsy for whole-genome DNA sequencing within the CPCT-02 study (NCT01855477). To evaluate whether biopsies were obtained from a 68Ga-PSMA positive lesion, rigid body image registration of 68Ga-PSMA PET/CT and interventional CT was performed. This technique provided volume of interest (VOI) based quantification of 68Ga-PSMA uptake at the exact biopsy site. In addition, the potential impact of molecular analyses on clinical decision making was evaluated.
Results
Sixty-nine 68Ga-PSMA-guided biopsies were eligible for primary analysis. Based on tumor percentage ≥ 30%, 70% of 68Ga-PSMA-guided biopsies was eligible for molecular analyses. At biopsy sites with positive, inconclusive or negative 68Ga-PSMA uptake, tumour percentage was ≥ 30% in 73%, 55% and 36% of the biopsies, respectively (p = 0.0850). At sites of biopsies with a tumour percentage ≥ 30%, standardized uptake value (SUV)max and SUVmean of 68Ga-PSMA were significantly higher (p = 0.0260 and p = 0.0129 respectively), whereas Hounsfield units (HU)mean and HUmax on CT were significantly lower (p = 0.0189 and p = 0.0494 respectively). Molecular analyses identified potentially targetable aberrations including PTEN loss, AR amplifications, and BRCA variants.
Conclusions
68Ga-PSMA PET/CT is a useful technique to improve the success rate of CT-guided bone biopsies for molecular analyses in mCRPC patients. Successful bone biopsies for molecular analyses can improve individual treatment planning by detecting targetable mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. de Wit: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy: Clovis. N. Mehra: Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Sanofi Genzyme; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Bayer. A.A.M. Van der Veldt: Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: MSD; Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (institution), Advisory / Consultancy: Novartis; Honoraria (institution), Advisory / Consultancy: Pierre Fabre; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Sanofi; Honoraria (institution), Advisory / Consultancy: Ipsen. M.P. Lolkema: Research grant / Funding (institution): JNJ; Research grant / Funding (institution): Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
2494 - CAR-T Nursing Education at a UK Specialist Cancer Hospital
Presenter: Rose Ellard
Session: Poster Display session 3
Resources:
Abstract
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract